The epidemiological programme is now complete, and, together with available other clinical and basic-science evidence, further supports the safety profile of insulin glargine as suggested earlier by its pharmacovigilance record (Diapedia)
Diabetes News Service
Glycosmedia is also available as an App:
For iPhone and iPad | For Android devices
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
